Combined Use of Cabozantinib and Nivolumab in Clinical Practice

Introduction. The present article discusses renal cancer, one of the common malignant diseases. Historical and modern therapies are considered, including tyrosine kinase inhibitors and immune checkpoint inhibitors. The results of clinical studies evaluating the efficacy of combined drug therapy are discussed, including the combination of immune checkpoint inhibitors with angiogenesis of targeted therapy.

Materials and methods. A case is presented of a patient with metastatic clear cell renal cell carcinoma with multiple lung metastases. The diagnosis was established using computed tomography data and was not verified. Various therapy regimens were used during treatment, including pazopanib, nivolumab, and the combination of nivolumab with cabozantinib.

Results and discussion. Follow-up examinations showed disease stabilization and normal tolerance of therapy. Eventually, the patient underwent laparoscopic cytoreductive nephrectomy. The therapy with nivolumab in combination with cabozantinib is still ongoing.

Conclusion. The combined use of cabozantinib and nivolumab currently constitutes a promising strategy for treating renal cell cancer, in which cabozantinib prevents tumor progression, and nivolumab increases immune system activity, promoting tumor cell destruction.

1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. DOI: 10.3322/caac.21660

2. Padala S.A., Barsouk A., Thandra K.C., Saginala K., Mohammed A., Vakiti A., et al. Epidemiology of renal cell carcinoma. World J Oncol. 2020;11(3):79–87. DOI: 10.14740/wjon1279

3. Jonasch E., Walker C.L., Rathmell W.K. Clear cell renal cell carcinoma ontogeny and mechanisms of lethality. Nat Rev Nephrol. 2021;17(4):245–61. DOI: 10.1038/s41581-020-00359-2

4. Heng D.Y., Xie W., Regan M.M., Harshman L.C., Bjarnason G.A., Vaishampayan U.N., et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 2013;14(2):141–8. DOI: 10.1016/S1470-2045(12)70559-4

5. Jacobsen J., Grankvist K., Rasmuson T., Bergh A., Landberg G., Ljungberg B. Expression of vascular endothelial growth factor protein in human renal cell carcinoma. BJU Int. 2004;93(3):297–302. DOI: 10.1111/j.1464-410x.2004.04605.x

6. Rini B.I. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions. Clin Cancer Res. 2007;13(4):1098–106. DOI: 10.1158/1078-0432.CCR-06-1989

7. Kaelin W.G. Jr. The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin Cancer Res. 2007;13(2 Pt 2):680s–4s. DOI: 10.1158/1078-0432.CCR-06-1865

8. Rassy E., Flippot R., Albiges L. Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma. Ther Adv Med Oncol. 2020;12:1758835920907504. DOI: 10.1177/1758835920907504

9. Moran M., Nickens D., Adcock K., Bennetts M., Desscan A., Charnley N., et al. Sunitinib for metastatic renal cell carcinoma: a systematic review and meta-analysis of real-world and clinical trials data. Target Oncol. 2019;14(4):405–16. DOI: 10.1007/s11523-019-00653-5

10. Escudier B., Porta C., Schmidinger M., Rioux-Leclercq N., Bex A., Khoo V., et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019;30(5):706–20. DOI: 10.1093/annonc/mdz056

11. Suyama K., Iwase H. Lenvatinib: a promising molecular targeted agent for multiple cancers. Cancer Control. 2018;25(1):1073274818789361. DOI: 10.1177/1073274818789361

12. Vecchio S.J.D., Ellis R.J. Cabozantinib for the management of metastatic clear cell renal cell carcinoma. J Kidney Cancer VHL. 2018;5(4):1–5. DOI: 10.15586/jkcvhl.2018.109

13. Bellesoeur A., Carton E., Alexandre J., Goldwasser F., Huillard O. Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy. Drug Des Devel Ther. 2017;11:2801–11. DOI: 10.2147/DDDT.S109640

14. Garcia J., Hurwitz H.I., Sandler A.B., Miles D., Coleman R.L., Deurloo R., et al. Bevacizumab (Avastin®) in cancer treatment: A review of years of clinical experience and future outlook. Cancer Treat Rev. 2020;86:102017. DOI: 10.1016/j.ctrv.2020.102017

15. Meskawi M., Valdivieso R., Dell’Oglio P., Trudeau V., Larcher A., Karakiewicz P.I. The role of everolimus in renal cell carcinoma. J Kidney Cancer VHL. 2015;2(4):187–94. DOI: 10.15586/jkcvhl.2015.43

16. Brown L.C., Desai K., Zhang T., Ornstein M.C. The Immunotherapy landscape in renal cell carcinoma. BioDrugs. 2020;34(6):733–48. DOI: 10.1007/s40259-020-00449-4

17. Aggen D.H., Drake C.G., Rini B.I. Targeting PD-1 or PD-L1 in metastatic kidney cancer: combination therapy in the first-line setting. Clin Cancer Res. 2020;26(9):2087–95. DOI: 10.1158/1078-0432.CCR-19-3323

18. Motzer R.J., Escudier B., McDermott D.F., George S., Hammers H.J., Srinivas S., et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373(19):1803–13. DOI: 10.1056/NEJMoa1510665

19. McDermott D.F., Huseni M.A., Atkins M.B., Motzer R.J., Rini B.I., Escudier B., et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med. 2018 Jun;24(6):749–57. DOI: 10.1038/s41591-018-0053-3

20. Motzer R.J., Rini B.I., McDermott D.F., Redman B.G., Kuzel T.M., Harrison M.R., et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol. 2015;33(13):1430–7. DOI: 10.1200/JCO.2014.59.0703

21. Motzer R.J., Jonasch E., Boyle S., Carlo M.I., Manley B., Agarwal N., et al. NCCN Guidelines insights: kidney cancer, version 1.2021. J Natl Compr Canc Netw. 2020;18(9):1160–70. DOI: 10.6004/jnccn.2020.0043

22. Tenold M., Ravi P., Kumar M., Bowman A., Hammers H., Choueiri T.K., et al. Current approaches to the treatment of advanced or metastatic renal cell carcinoma. Am Soc Clin Oncol Educ Book. 2020;40:1–10. DOI: 10.1200/EDBK_279881

23. Roland C.L., Lynn K.D., Toombs J.E., Dineen S.P., Udugamasooriya D.G., Brekken R.A. Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer. PLoS One. 2009;4(11):e7669. DOI: 10.1371/journal.pone.0007669

24. Furukawa K., Nagano T., Tachihara M., Yamamoto M., Nishimura Y. Interaction between immunotherapy and antiangiogenic therapy for cancer. Molecules. 2020;25(17):3900. DOI: 10.3390/molecules25173900

25. Lee W.S., Yang H., Chon H.J., Kim C. Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascularimmune crosstalk to potentiate cancer immunity. Exp Mol Med. 2020;52(9):1475–85. DOI: 10.1038/s12276-020-00500-y

26. Choueiri T., Powles M., Burotto M., Bourlon M.T., Zurawski B., Oyervides Juárez V.M., et al. 696O_PR Nivolumab + cabozantinib vs sunitinib in first‐line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial. Ann Oncol. 2020;31(suppl_4):S1142–215. DOI: 10.1016/j.annonc.2020.08.2257

27. Motzer R., Tykodi S., Escudier B., Oudard S., Hammers H.J., McDermott D.F., et al. Final analysis of the CheckMate 025 trial comparing nivolumab (NIVO) versus everolimus (EVE) with >5 years of follow‐up in patients with advanced renal cell carcinoma (aRCC). J Clin Oncol. 2020;38 (suppl 6; abstr 617). DOI: 10.1200/JCO.2020.38.6_suppl.617

28. Tsimafeyeu I., Zolotareva T., Varlamov S., Zukov R., Petkau V., Mazhbich M., et al. Five-year survival of patients with metastatic renal cell carcinoma in the Russian Federation: results from the RENSUR5 Registry. Clin Genitourin Cancer. 2017;15(6):e1069–72. DOI: 10.1016/j.clgc.2017.07.017